[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

615A.O1.6 Acute Myeloid Leukemia - Therapy, excluding Transplantation: Pediatric and Adult AML Therapy

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 6, 2010: 7:00 AM-8:30 AM
311 EFGH (Orange County Convention Center)
Moderators:
Jessica K. Altman, MD, Northwestern University Feinberg School of Medicine and William Blum, MD, The Ohio State University Comprehensive Cancer Center
7:00 AM
Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased ToxicityClinically Relevant Abstract

Ursula Creutzig, MD1, Martin Zimmermann2*, Michael Dworzak, M.D.3*, Jean-Pierre Bourquin, MD, PhD4, Christine Neuhoff5*, Annette Sander5*, Jan Stary6* and Dirk Reinhardt, MD, PhD7

1Hematology/Oncology, University Children's Hospital Muenster, Muenster, Germany
2Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
3Department of Pediatric Hematology/Oncology, St. Anna Children's Hospital, Vienna, Vienna, Austria
4Div. of Pediatric Oncology, Universitaets-Kinderklinik Zurich, Zurich, Switzerland
5Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
6Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University Prague, Prague, Czech Republic
7Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany

7:15 AM
Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531Clinically Relevant Abstract

Alan S Gamis, MD, MPH1, Todd A Alonzo, PhD2, Robert B Gerbing, MS3*, Richard Aplenc, MD4, Lillian Sung, MD, PhD5, Soheil Meshinchi, MD, PhD6, Susana C. Raimondi, PhD7, Betsy A. Hirsch, PhD8*, Samir Kahwash, MD9*, Amy Heerema-McKenney, MD10*, Laura Winter, PharmD11*, Kathleen Glick, CCRP12*, Patti Byron, RN13*, Laura Burden3*, Tanya Wallas, MS3*, Stella M. Davies, MBBS, PhD14 and Franklin O. Smith, MD15

1Children's Mercy Hospitals & Clinics, Kansas City, MO
2Keck School of Med. Dept. of Preventive Medicine, Univ. of Southern California, Arcadia, CA
3Children's Oncology Group, Arcadia, CA
4Children's Hospital of Philadelphia, Philadelphia, PA
5Dept. of Pediatrics, Div. of Hem./Onc., The Hospital for Sick Children, Toronto, ON, Canada
6Clinical Research, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA
7Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
8Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, MN
9Nationwide Children's Hospital, Columbus, OH
10Stanford University Medical Center
11Seattle Childrens Hospital, Seattle, WA
12Maine Children's Cancer Program, Scarborough, ME
13British Columbia Children's Hospital, Vancouver, BC, Canada
14Cincinnati Children's Hospital Medical Center, Cincinnati, OH
15Div. of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

7:30 AM
Outcome of Adolescents and Young Adults (AYAs) with Non-M3 Acute Myeloid Leukemia (AML) Treated on Children’s Oncology Group (COG) Trials Compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) TrialsClinically Relevant Abstract

Anna R.K. Franklin, M.D.1, Todd A. Alonzo, PhD2, Robert B. Gerbing3*, Kathleen Donohue, M.A.4*, Megan Othus, PhD5*, John Horan6*, Elihu H. Estey, MD7, Richard A. Larson, MD8 and William G. Woods, MD9

1Pediatrics, M.D. Anderson Cancer Center, Houston, TX
2Keck School of Medicine, University of Southern California, Los Angeles, CA
3Children's Oncology Group, Arcadia, CA
4Duke Universiy, Durham, NC
5Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
6Pediatrics, Emory University, Atlanta, GA
7Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
8The University of Chicago Medical Center, Chicago, IL
9Aflac Cancer Center & Blood Disorders Service, Children's Healthcare of Atlanta/Emory University, Atlanta, GA

7:45 AM
Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01Clinically Relevant Abstract

Gertjan Kaspers1, Martin Zimmermann2*, Dirk Reinhardt2, Brenda Gibson3, Rienk Tamminga1*, Olga Aleinikova4*, Hortensia Armendariz5*, Michael Dworzak6*, S. Ha7*, Lisa Hovi8*, Alexei Maschan9*, Andre Baruchel10, Yves Bertrand10*, Bassem Razzouk11, Carmelo Rizzari12*, Petr Smisek13*, Owen Smith3*, Batia Stark14* and Ursula Creutzig2

1DCOG, Amsterdam, Netherlands
2BFM-AML Group, Germany
3UK CCLG, United Kingdom
4Moscow-Minsk, Belarus
5GATLA, Argentina
6BFM-A, Austria
7Hong Kong, Hong Kong
8NOPHO, Finland
9Moscow-Minsk, Russia
10CLCG, France
11St. Jude, TN
12AIEOP, Italy
13CPH, Czech Republic
14Israel, Israel

8:00 AM
Prospective Phase III Trial of Valproic acid  (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 StudyClinically Relevant Abstract

Michela Tassara1*, Veronika Hofer1*, Konstanze Döhner2*, Marie Lilienfeld-Toal3*, Gerhard Held4*, Katharina Götze5*, Heinz A. Horst, MD6, Sibylla Wilhelm, MD7*, Stephan Kremers, CA, MD8*, Elisabeth Koller9*, Daniela Späth1*, Silja Mack1*, Carina Morlok1*, Martin Göttlicher10*, Hartmut Döhner, MD2* and Richard F. Schlenk, MD11

1Internal Medicine III, University of Ulm, Ulm, Germany
2Universitätsklinikum Ulm, Ulm, Germany
3Internal Medicine, Univerity of Bonn, Bonn
4Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany
5Medical Clinic III, Klinikum Rechts der Isar der Technischen Universität München, Munich
6University of Schleswig-Holstein , Kiel, Germany
7Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
8Caritas-Krankenhaus Lebach, Lebach, Germany
9Internal Medicine III, Hanuschkrankenhaus, Vienna, Austria
10Toxicology, HelmholtzZentrum München, Neuherberg
11University Hospital of Ulm, Ulm, Germany

8:15 AM
Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Judith E. Karp, MD1, John M. Pagel, MD, PhD2, B. Douglas Smith, MD3, Jacqueline M Greer, RN4*, D. Michelle Drye, RN3*, Kelly M. Smith, MD5, Kathleen Dorcy, RN2*, John J Wright, MD, PhD6*, L. Austin Doyle, MD, PhD6*, Elizabeth Garrett-Mayer, PhD7* and Elihu H. Estey, MD8

1Department of Oncology, Division of Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center at John Hopkins , Baltimore, MD
2Fred Hutchinson Cancer Research Ctr., Seattle, WA
3at Johns Hopkins, Kimmel Cancer Center, Baltimore, MD
4Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
5University of Washington Medical Center, Tukwila, WA
6National Cancer Institute, Bethesda, MD
7Medical University of South CArolina, Charleston, SC
8Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

*signifies non-member of ASH